Skip to content
In English |
En español
Search
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 78 for your search:
Cancer Type/Condition:
Brain tumor, adult: General and other
Stage/Subtype:
mixed glioma, adult
Country:
U.S.A.
Trial Type:
Treatment
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase III Randomized Study of Radiotherapy Alone Versus Radiotherapy With Concurrent and Adjuvant Temozolomide Versus Temozolomide Alone in Patients With Newly Diagnosed 1p/19q Codeleted Anaplastic Glioma
Phase:
Phase III
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCCTG-N0577
, N0577, NCT00887146
2.
Phase III Randomized Study of Radiotherapy With Versus Without Temozolomide in Patients With Symptomatic or Progressive Low-Grade Gliomas
Phase:
Phase III
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
ECOG-E3F05
, E3F05, NCT00978458
3.
Phase I/II Study of Imatinib Mesylate in Patients With Recurrent Oligodendroglioma or Mixed Oligoastrocytoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCCTG-N0272
, N0272, NCT00049127
4.
A Phase I/II Study of the Photon Radiosurgery System
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
2 to 32
Sponsor:
Other
Protocol IDs:
CNS 0201
, NCT00179907
5.
Phase I/II Study of Carboplatin, Melphalan, and Etoposide Phosphate in Combination With Blood-Brain Barrier Disruption With Mannitol and Delayed Sodium Thiosulfate in Patients With Anaplastic Oligodendroglioma or Oligoastrocytoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 to 75
Sponsor:
NCI
Protocol IDs:
OHSU-8507
, OHSU-2868, OHSU-SOL-04058-L, NCT00303849
6.
Phase I/II Study of ZD6474 in Patients With Recurrent High-Grade or Progressive Low-Grade Gliomas
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-06-C-0063
, NCI-P6680, NCT00293566
7.
Intracerebral Clysis in Treating Patients With Recurrent Primary Brain Tumors
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
1 to 120
Sponsor:
Other
Protocol IDs:
R01 CA 89395-01
, Topotecan, Brain Tumors, Intracerebral Clysis, NCT00452959
8.
Phase I/II Study of Erlotinib Hydrochloride and Sirolimus in Patients With Recurrent Malignant Glioma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
UCLA-0604104
, OSI3781s, NCT00509431
9.
Phase I/II Study of VNP40101M and Temozolomide in Patients With Progressive or Relapsed Malignant Glioma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Over 18
Sponsor:
NCI
Protocol IDs:
NU07C1
, NU 07C1, NCT00516282
10.
Safety and Efficacy Study of REOLYSIN® in the Treatment of Recurrent Malignant Gliomas
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
REO 007
, NCT00528684
11.
Vorinostat, Isotretinoin and Carboplatin in Adults With Recurrent Glioblastoma Multiforme (GBM)
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
2006-0709
, NCT00555399
12.
LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
08-342
, CLBH589BUS42T, NCT00859222
13.
Phase I/II Study of Dasatinib And Bevacizumab in Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCCTG-N0872
, N0872, NCT00892177
14.
Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
00016446
, NCT00939991
15.
Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Glioma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
3 to 25
Sponsor:
NCI, Other
Protocol IDs:
CDR0000437085
, SJCRH-SJHG04, GENENTECH-OSI3160s, NCT00124657
16.
Proton Beam Radiation Therapy in Treating Patients With Low Grade Gliomas
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
UPCC 08309
, NCI-2009-01442, NCT01024907
17.
Phase I/II Study of Temsirolimus and Perifosine in Patients With Recurrent or Progressive Malignant Glioma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
MSKCC-09058
, 09-058, 8249, NCT01051557
18.
Phase II Randomized Study of Intra-arterial Carboplatin, Cyclophosphamide, and Etoposide or Etoposide Phosphate With or Without Delayed High-Dose Sodium Thiosulfate in Patients With High-Grade Glioma
Phase:
Phase II
Type:
Supportive care, Treatment
Status:
Active
Age:
18 to 75
Sponsor:
NCI
Protocol IDs:
OHSU-7328
, OHSU-922, OHSU-ONC-02059-L, NCT00075387, CASE-CCF-6385
19.
Phase II Study of Tamoxifen and Bortezomib in Patients With Recurrent High-Grade Gliomas
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-05-C-0137
, NCT00112762
20.
Phase II Study of Temozolomide in Patients With Supratentorial Low-Grade Glioma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
UCSF-99102
, BTRC-9902, UCSF-H7858-16278-07, NCT00313729
21.
Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 to 70
Sponsor:
Other
Protocol IDs:
05-079
, NCT00200161
22.
Assessing the Suitability of an Imaging Probe for Use in Clinical Cell and Gene Therapy Trials in Cancer and Rheumatoid Arthritis
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
BRNCNS0003
, 95908, BRNCNS0003, NCT00185848, NCT00185848
23.
Phase II Study of Bevacizumab in Patients With Recurrent High-Grade Glioma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-06-C-0064
, NCI-P6762, NCT00290797
24.
Pazopanib In Combination With Lapatinib In Adult Patients With Relapsed Malignant Glioma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
VEG102857
, NCT00350727
25.
Phase II Study of Intrathecal Iodine I 131 Monoclonal Antibody 3F8 in Patients With GD2-Expressing Central Nervous System or Leptomeningeal Neoplasms
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Any age
Sponsor:
Other
Protocol IDs:
MSKCC-05122
, NCT00445965
Select All on Page
1
Help with Results
